To investigate the degree of absorption of flavan-3-ols in the small intestine, human subjects with an ileostomy ingested 200 mg of Polyphenon E, a green tea extract, after which ileal fluid and urine, collected over a 24-h period, were analyzed by high-performance liquid chromatography with photodiode array and mass spectrometric detection. The data obtained indicated that although ;40% of flavan-3-ol intake is recovered in ileal fluid, substantial quantities are absorbed in the small intestine. Moreover, 14 urinary metabolites, comprising sulfates, glucuronide, and methylated derivatives, were identified and quantified. All were metabolites of (epi)catechin or (epi)gallocatechin, representing 47 6 2% and 26 6 9%, respectively, of the ingested parent compound. These high recoveries indicate that these flavan-3-ols absorbed in the small intestine are much more bioavailable than most dietary flavonoids. No 3-O-galloylated flavan-3-ols or their metabolites were detected in urine. The absence of urinary flavan-3-ol metabolites after ingestion of 200 mg of (-)-epigallocatechin gallate indicates that there is no removal of the 3-O-galloyl group in vivo, and hence, this does not account for the high urinary recovery of (epi)gallocatechin metabolites after ingestion of Polyphenon E. Increasing the intake of Polyphenon E, by feeding doses of 200, 500, and 1500 mg, led to increased urinary excretion of (epi)catechin metabolites but not metabolites of (epi)gallocatechin. Coingestion of 200 mg of Polyphenon E with bread, cheese, or glucose did not significantly modify the absorption, metabolism, and excretion of flavan-3-ols. It does not necessarily follow, however, that the same would occur when flavan-3-ols are ingested with more complex food matrices. J. Nutr. 138: 1535S-1542S, 2008 
Introduction
Tea, produced principally from infusions of dried leaves of Camellia sinensis, is, after water, the most widely consumed beverage in the world. Epidemiological studies have linked tea consumption, notably green tea, with reduced incidence of cardiovascular disease (1-3) and cancer (2) . However, some other studies and meta-analyses have found inconclusive relations between tea consumption and health effects (4) (5) (6) (7) . Protective effects of green tea have been attributed to their polyphenol content, the most abundant compounds being a group of 8 flavan-3-ols (catechins) ( Fig. 1) (8) , which are known to be potent antioxidants. The main flavan-3-ol and the most potent antioxidant in most green teas is (-)-epigallocatechin-3-gallate (8, 9) , although in some less common teas (-)-epicatechin gallate predominates (10) .
Numerous studies have assessed the potential health benefits of green tea catechins using a variety of in vivo and in vitro models. Ingestion of green tea has been shown to increase antioxidant status of plasma in humans (11, 12) . Green tea catechins may reduce the risk of cardiovascular disease because of their hypolipemic (13) (14) (15) (16) (17) , antiatherosclerotic (18) , and antihypertensive effects (19) . They also have antidiabetic (13, 20) , antiangiogenic (21) , antiobesity (21) (22) (23) and antiinflammatory properties (24, 25) . In addition, flavan-3-ols have shown beneficial effects on human vascular function (26) and possibly osteoarthritis (27) .
Green tea and catechins also have anticarcinogenic and antimutagenic effects (28, 29) , have a chemopreventive action on lung tumorigenesis (30) and prostate (31) and breast cancer (32) , and induce apoptosis of carcinoma cells (33) . They have also been reported to exert antiviral, antibacterial (34) , and neuroprotective effects (35, 36) as well as having a capacity to prevent gastrointestinal disorders (37) and improve muscular function in dystrophy models (38) .
After ingestion of green tea, flavan-3-ols are absorbed and metabolized and appear in blood and urine (39) (40) (41) . Flavan-3-ols, including (-)-epigallocatechin-3-gallate, have been detected in blood as intact forms and metabolites and reach micromolar concentrations in plasma (42) (43) (44) . Absorption appears to take place in the small intestine, with unabsorbed compounds reaching the colon, where they undergo extensive bacterial degradation (45, 46) .
Despite a wealth of data on bioavailability of green tea flavan-3-ols (47) , little is known about their absorption in the small intestine and how it can be affected by the presence of other food components, the so-called matrix effect. Human subjects with an ileostomy provide a useful model for studying the absorption of micronutrients as analysis of ileal fluid after supplementation provides information of their fate in the small intestine without the complications of interactions with the colonic microflora.
In this study, the intestinal fate of flavan-3-ols after ingestion of different doses of a green tea extract was investigated, along with the effect of the food matrix on absorption and metabolism.
Materials and Methods
Materials. Mitsui Norin supplied a green tea extract, Polyphenon E, as well as (2)-epigallocatechin-3-gallate extracted from green tea and standards for (1)-catechin, (-)-epicatechin, (1)-gallocatechin, (-)-epigallocatechin, (1)-gallocatechin gallate, (-)-epigallocatechin gallate, (1)-catechin gallate, and (-)-epicatechin gallate. Ethyl gallate was obtained from Sigma. HPLC solvents were supplied by Rathburn Chemicals. Gelatin capsules were obtained from Agar Scientific. White bread, glucose tablets, and full-fat cheese were purchased from a local supermarket.
Feeding protocol. The study protocol was approved by the Glasgow Royal Infirmary Research Ethics Committee. Five ileostomy volunteers (3 male and 2 female) were recruited and gave their written informed consent. Ileostomy subjects had undergone a total colostomy but had a normal small intestine and were otherwise healthy. All subjects followed a low-flavonoid diet for 2 d before the study by avoiding all fruits and vegetables, alcoholic beverages, cocoa, coffee, and tea. After an overnight fast, the volunteers consumed a capsule containing 200 mg of Polyphenon E on its own or with either 2 slices of white bread, 3 glucose tablets (10.2 g), or 3 portions of a full-fat cheese (49.8 g of ''Laughing Cow'' cheese, 45% fat). In the study on the effect of dose, volunteers consumed capsules containing either 200, 500, or 1500 mg of Polyphenon E. In a third feed, volunteers consumed a 200-mg capsule of (-)-epigallocatechin gallate that contained 3% (-)-epigallocatechin as an impurity. Ileal fluid and urine were collected before the intake of the capsules (time 0 h) and over a 24-h period after supplementation. After the volumes of ileal fluid and urine that were collected had been recorded, aliquots were acidified to pH 3 with 50% aqueous formic acid before being stored at -80°C.
Sample preparation. Polyphenon E was dissolved at 10 g/L of methanol, after which 10-mL aliquots were analyzed in triplicate by HPLC with photodiode array and mass spectrometric detection (HPLC-PDA-MS). Urine samples were defrosted, thoroughly mixed, and centrifuged at 16,100 3 g for 20 min at 4°C. Triplicate 100-mL aliquots of the supernatant were then analyzed by HPLC-PDA-MS n . The extraction of ileal fluid was carried out as follows: 2.5-g aliquots were mixed with 10 mL of a 50% aqueous methanol solution containing 1% formic acid, and 20 mmol/L diethyldithiocarbamate and 2 mg ethyl gallate as an internal standard were added. The mixture was blended for 1 min using an Ultra Turrax homogenizer (T-25, IKA-WERKE). Samples were further extracted for 30 min using an orbital shaker (IKA-WERKE) before being centrifuged at 4900 3 g for 20 min at 4°C. The resulting supernatant was collected and the pellets reextracted using methanol containing 1% formic acid and 20 mM diethyldithiocarbamate using the same protocol. The 2 supernatants were mixed and reduced to dryness in vacuo. Samples were resuspended in 1 mL of 10% aqueous methanol containing 0.1% formic acid and centrifuged at 16,100 3 g for 20 min at 4°C. Triplicate 20-mL samples of the supernatant were analyzed by HPLC-PDA-MS n .
HPLC-PDA-MS. Samples were analyzed on a Surveyor HPLC system comprising of a HPLC pump, PDA detector, scanning from 250 to 700 nm, and an autosampler cooled to 4°C (Thermo Finnigan). Separation was carried out using a 250 3 4.6 mm i.d. 4 mm Synergi RP-Max column (Phenomenex) maintained at 40°C and eluted at a flow rate of 1 mL/min with either a gradient over 30 min of 5-25% acetonitrile in 0.1% aqueous formic acid (analysis of ileal fluid and Polyphenon E) or a gradient over 45 min of 5-30% acetonitrile in 0.1% aqueous formic acid (analysis of urine). After passing through the flow cell of the PDA detector, the column eluate was split, and 0.3 mL/min was directed to a LCQ Duo ion trap mass spectrometer adapted for MS n analysis and fitted with an electrospray interface (Thermo Finnigan) operating in negative ion mode. Analyses were initially carried out using full-scan, data-dependent MS 2 scanning from m/z 100 to 2000. Compound identities were confirmed by MS 3 consecutive reaction monitoring, collision energy 35%. For instance, identification of methyl-(epi)catechin sulfate metabolites involved isolation and fragmentation of the m/z 383 ion. The resulting methyl-(epi)catechin ion at m/z 303 (80 amu loss of a sulfate moiety) was then selected for further fragmentation. The resulting MS standards. This analysis principle was applied to the identification of all flavan-3-ol metabolites.
Flavan-3-ols in ileal fluid and Polyphenon E were quantified using absorption at 280 nm by reference to standard calibration curves. Quantification of flavan-3-ol metabolites in urine was carried out using selected ion monitoring (SIM). The conditions used were as outlined above except that the mass spectrometer was set up to monitor specific ions. For quantifying (epi)gallocatechin glucuronide, methyl-(epi)gallocatechin glucuronide, and methyl-(epi)gallocatechin sulfate, the parent ions were m/z 481, m/z 495, and m/z 399, respectively. No standards of these compounds were available, so (-)-epigallocatechin was used as a calibration standard. For quantifying (epi)catechin glucuronide, (epi)-catechin sulfate, and methyl-(epi)catechin sulfate, the parent ions were m/z 465, m/z 369, and m/z 383, respectively. No standards of these compounds were available, so (-)-epicatechin was used as a calibration standard.
Statistical analysis. Values in the text and tables are means 6 SEM. Statistical differences are assessed by ANOVA for repeated measures followed by the Tukey-Kramer test using Statview 5 software (SAS Institute). Differences were considered significant at P , 0.05.
Results
Quantification of flavan-3-ols in Polyphenon E. HPLC-PDA-MS n analysis showed that 200 mg of Polyphenon E contained a total of 452 6 3 mmol (n ¼ 3) of monomeric flavan-3-ols. (-)-Epigallocatechin-3-gallate was the major component (310 6 4 mmol) comprising 69% of the total flavan-3-ols, followed by (-)-epicatechin (71 6 1 mmol), (-)-epicatechin-3-gallate (32 6 1 mmol), and (2)-epigallocatechin (18 6 2 mmol). Their (1)-epimers are also present but in relatively small amounts with a total of 21.6 mmol (see Supplemental Data). The notable difference between the flavan-3-ol content of Polyphenon E and green tea infusions is that teas contain much higher levels of (-)-epigallocatechin as well as substantial amounts of gallic acid, chlorogenic acids, flavonols, and caffeine (8) .
Identification of flavan-3-ols in ileostomy fluid. The identification of flavan-3-ols in ileal fluid was carried out using HPLC-PDA-MS 3 . Ileal fluid collected after the ingestion of 200 mg of Polyphenon E contained only (-)-epicatechin, (-)-epicatechin gallate, (-)-epigallocatechin gallate, and (1)-gallocatechin gallate in amounts quantifiable by HPLC-PDA at 280 nm. MS also detected trace amounts of flavan-3-ol metabolites, principally sulfated derivatives, but in amounts that were below the limits of quantification by PDA detection.
Identification of flavan-3-ol metabolites in urine. Urine samples collected after ingestion of 200 mg of Polyphenon E were also analyzed by HPLC-PDA-MS n . None of the original Polyphenon E flavan-3-ols was present, but 14 metabolites of (epi)catechin and (epi)gallocatechin were detected. Without reference compounds, the relative portion of (1)-and (-)-enantiomers of the various metabolites could not be determined and might be different from the proportions present in the ingested flavan-3-ol supplement (48, 49) . It was therefore not possible to distinguish between (-)-epicatechin and (1)-catechin metabolites and also (-)-epigallocatechin and (1)-gallocatechin derivatives. No metabolites of either (epi)catechin gallate or (epi)gallocatechin gallate were detected. The identification of the complex array of glucuronide, sulfate, and methyl metabolite isomers of (epi)catechin and (epi)gallocatechin (Fig. 2) was based on the following criteria (also see online material).
Peak 1 (t R ¼ 14.1 min) had a negatively charged molecular ion ([M-H]
2 ) at m/z 481, which on MS 2 produced a fragment ion corresponding to (epi)gallocatechin at m/z 305. ion at m/z 289. MS 3 of the m/z 289 ion yielded fragments characteristic of (epi)catechin, indicating that this peak is an (epi)catechin glucuronide, possibly (-)-epicatechin-3#-glucuronide (Fig. 3) , which has been identified in urine collected after oral ingestion of (-)-epicatechin by humans (51 , produced a m/z 303 fragment indicative of the cleavage of a SO 3 unit. MS 3 of the m/z 303 ion yielded a mass spectrum corresponding to that of a methyl-(epi)catechin. Moreover, with peaks 13 and 14, MS 3 of m/z 303 ion produced an ion at m/z 137, specific for methylation on position 4# of the B ring (50) . Therefore, peaks 8, 10, 11, and 12 are methyl-(epi)catechin sulfates, where the position of methylation is unknown, whereas peaks 13 and 14 are 4#-methyl-(epi)catechin sulfates.
After the initial qualitative analysis, urine samples were analyzed by HPLC with MS in SIM mode, and typical HPLC-SIM traces that were obtained and used to quantify the 14 individual flavan-3-ol metabolites are illustrated in Figure 2 .
Food matrix effects. In order to investigate potential matrix effects, 200 mg of Polyphenon E was ingested either on its own or with either bread, glucose tablets, or cheese, after which 24-h ileal fluid and urine were collected and analyzed quantitatively. The quantities of flavan-3-ols in ileal fluid are summarized in Table 1 . The overall recoveries of flavan-3-ols ranged from 39% to 48% of intake; however, the average recovery of (-)-epicatechin and (-)-epigallocatechin was 27 6 2% of intake compared with 60 6 3% for (-)-epigallocatechin gallate and (1)-gallocatechin gallate. When incubated in vitro with gastric juice for 1 h and ileal fluid for 4 h at 37°C, there was ;90% recovery of Polyphenon E flavan-3-ols (data not shown). Thus, the differential recoveries in ileal fluid after ingestion of Polyphenon E indicate that (-)-epicatechin and (-)-epicatechin gallate may be absorbed in the small intestine more efficiently than (-)-epigallocatechin gallate and (1)-gallocatechin gallate. Statistical analysis showed no significant effects of either bread, glucose, or cheese on the recoveries of flavonols in ileal fluid, indicating that their absorption in the small intestine was not subject to a matrix effect ( Table 1) .
Levels of 14 individual flavan-3-ol metabolites in urine of ileostomy volunteers were analyzed by HPLC-SIM (Fig. 2) , and the quantities of the 6 different types of metabolites are presented in Table 2 . No unmetabolized flavan-3-ols were detected in any of the urine samples. When Polyphenon E was ingested by itself, a total of 42 6 11 mmol of flavan-3-ol metabolites, equivalent to 9.2 6 2.4% of intake, was excreted in urine 24 h postingestion. The majority of the excreted compounds were metabolites of (epi)catechin (36 6 9 mmol, 47 6 12% of intake), principally as sulfate and methyl sulfate derivatives. (Epi)gallocatechin metabolites were excreted in lower quantities (5.7 6 1.9 mmol, 26 6 9% of intake), mainly as the methyl-(epi)gallocatechin sulfates, peaks 6 and 7. No 3-O-galloylated flavan-3-ol metabolites were detected. Statistical analyses show no significant differences in metabolite excretion between ingestion of Polyphenon alone and with either bread, glucose, or cheese (Table 2) . Dose effects. After ingestion of either 200, 500, or 1500 mg (452, 1130, and 3390 mmol) of Polyphenon E, there were dosedependent statistically significant increases in the overall levels of flavan-3-ol appearing in ileal fluid collected over a 24-h period (Table 3) . However, when total flavan-3-ol levels were expressed as a percentage of intake, figures of 43 6 11%, 50 6 7%, and 73 6 12%, were obtained, with only the latter value, for the highest dose, being significantly different (P , 0.001). When the levels of individual flavan-3-ols in the ileal fluid are considered, they followed a broadly similar profile except for a lower percentage recovery with the 1500-mg intake. The exception was (-)-epigallocatechin gallate, the major flavan-3-ol in Polyphenon E, which had an 87% recovery with the 1500-mg intake. These findings provide no evidence to suggest that the 3-O-galloyl flavonols undergo cleavage of the gallate moiety during passage through the small intestine.
The overall quantities of urinary flavan-3-ol metabolites increased significantly with amount of Polyphenon E ingested. When expressed as a percentage of intake, the recoveries were 9.3 6 2.4%, 9.7 6 2.7%, and 7.9 6 0.8%. These values are not significantly different, although once again there are differences in the recoveries of metabolites of (epi)gallocatechin and Table 4 ). The excretion of (epi)gallocatechin metabolites, 5.7 6 1.9, 3.0 6 0.8, and 5.3 6 1.2 mmol changed little with increasing dose. However, when expressed as a percentage of (epi)gallocatechin intake, the 26 6 9% obtained with the 200-mg dose fell to 5.5 6 1.4% and 3.3 6 0.6% at the 2 highest intakes. In contrast, the level of excretion of (epi)catechin metabolites, 47 6 12%, 56 6 14%, and 45 6 4% of intake, did not decline significantly with increased dose. This indicates that at higher Polyphenon E intakes, the systems responsible for absorption, metabolism, and excretion of (epi)catechins, in contrast to those for (epi)gallocatechins, appear not to be subject to saturation effects.
(-)-Epigallocatechin gallate ingestion. Five volunteers each consumed a capsule containing 186 mg of (-)-epigallocatechin gallate (407 mmol) and 14 mg of (-)-epigallocatechin (46 mmol). Over the next 24 h, 235 6 36 mmol of (-)-epigallocatechin gallate and 10.4 6 6.7 mmol of (-)-epigallocatechin were collected in ileal fluid, which represent recoveries of 58 6 9% and 34 6 22%, respectively. Thus, the ileal fluid contained 96% (-)-epigallocatechin gallate and 4% (-)-epigallocatechin. This ratio is very similar to that of the ingested supplement and indicates that removal of the 3-O-galloyl group from (-)-epigallocatechin gallate did not occur to any extent. Urine collected in the same study did not contain detectable quantities of any flavan-3-ols or flavan-3-ol metabolites including 4-O-methyl-gallic acid, even when samples were concentrated before analysis.
Discussion
Flavan-3-ol levels, in ileal fluid collected 0-24 h after ingestion of 200 mg of Polyphenon E, when expressed as a percentage of intake, show the average recovery of (-)-epicatechin and (-)-epigallocatechin to be 27 6 2% compared with 59 6 3% for (-)-epicatechin gallate and (-)-epigallocatechin gallate. In vitro incubations in gastric juice and ileal fluid indicated that the Polyphenon E flavan-3-ols are stable in the stomach and small intestine, so the recoveries in ileal fluid imply that (-)-epicatechin and (-)-epigallocatechin are absorbed into the circulatory system from the small intestine more efficiently than their 3-O-galloylated analogs. The data obtained with ileal fluid ( Table 1 ) also indicate that in healthy humans with an intact colon, substantial quantities of Polyphenon E flavan-3-ols, principally (-)-epigallocatechin gallate, will pass from the small to the large intestine, where they will become subject to breakdown by colonic bacteria to produce phenolic acids such as di-and trihydroxyphenyl-g-valerolactones (Fig. 3) (52-54) .
Analysis of the urine of ileostomy volunteers showed that the predominant compounds to be excreted were sulfates of (epi)catechin and methyl-(epi)catechin (Table 2) . No 3-O-galloylated flavan-3-ols or their metabolites were detected. The overall urinary excretion of (epi)catechin metabolites was 36 6 9 mmol, which is 47 6 12% of the ingested (epi)catechin. Although (epi)gallocatechin metabolites were excreted in smaller quantities, 5.7 6 1.9 mmol, this nonetheless represented 26 6 9% of (epi)gallocatechin intake. Thus, both (epi)catechins and (epi)gallocatechins are highly bioavailable.
In keeping with recoveries after ingestion of Polyphenon E (Tables 3 and 4 (6,7) 3.9 6 1.4 3.5 6 1.4 8.7 6 4.3 4.1 6 2.5 Total (epi)gallocatechin metabolites 5.7 6 1.9 (26 6 9) 6.2 6 2.6 (28 6 12) 10 6 5 (45 6 23) 5.3 6 2.9 (24 6 13) (Epi)catechin metabolites (2)-Epicatechin-3#-glucuronide (3) 3.4 6 0.8 3.6 6 0.8 6.4 6 2.5 2.6 6 0.6 (Epi)catechin sulfates (4, 5, 9) 18 6 5 9.6 6 4.0 9.5 6 4. was detected in urine after ingestion of either Polyphenon E or (-)-epigallocatechin gallate. Urinary 4-O-methyl-gallic acid, a metabolite of gallic acid, is a marker of tea consumption (55), but unlike green tea and black tea (8) , Polyphenon E does not contain gallic acid. Although (-)-epigallocatechin gallate is not excreted in urine, several earlier studies have detected it in the bloodstream, principally in an unmetabolized form, with a peak plasma concentration (C max ) in the high nanomolar to low micromolar range after ingestion of Polyphenon E (39, 41, 43) . This is very unusual from 2 perspectives. First, following absorption, flavonoids typically appear in the bloodstream as sulfate and glucuronide conjugates, and once absorbed, they are invariably excreted, sometimes after being subjected to further metabolism (56) .
The absence of (-)-epigallocatechin gallate in human urine, despite reaching plasma C max 1.44 h after ingestion of 200 mg of Polyphenon E, and having an elimination half-life of 1.9 h (41), is of interest. It is possible that the kidneys are unable to remove (-)-epigallocatechin gallate from the bloodstream, but if this is the case, there must be other mechanisms that result in the rapid decline after C max has been reached. Studies in which tritiumlabeled (-)-epigallocatechin gallate was injected intravenously into bile-duct-cannulated rats have shown that 57% of the injected radioactivity was excreted in bile within 4 h, and 77% within 48 h, compared with 2% in urine over the 48-h period (57) . This involved extensive metabolism of the (-)-epigallocatechin gallate, as it was present in bile as sulfo-and/or glucuronide conjugates of 4$-methyl-and 4#,4$-dimethyl-(-)-epigallocatechin gallate (Fig. 3) . In an earlier study in which a relatively high dose of (-)-epigallocatechin gallate [;400 mg/kg body weight, equivalent to a 70-kg, 170-cm-tall human ingesting 16.6 g of (-)-epigallocatechin gallate] was fed to rats by gavage, only ;3% of intake was detected in bile, principally as metabolites (58) . To what extent enterohepatic recirculation of (-)-epigallocatechin gallate metabolites occurs in humans has not been established. If it were a significant event in the present study, then (-)-epigallocatechin gallate metabolites should have been detected in substantial amounts in ileal fluid. This did not occur; although flavan-3-ol metabolites, principally sulfated derivatives, were detected by MS, they were in amounts that were below the limits of quantification by PDA detection and were very minor components compared with the unmetabolized flavan-3-ols. This is a topic that requires further investigation.
The feeding studies also revealed that not bread, glucose, or cheese affected the absorption of Polyphenon E flavan-3-ols in the small intestine or the urinary excretion of flavan-3-ol metabolites (Tables 1 and 2 ). It does not necessary follow, however, that the same would occur when flavan-3-ols are ingested with more complex food matrices.
The feeding studies in which volunteers with an ileostomy ingested either 200, 500, or 1500 mg of Polyphenon E revealed some interesting findings that complement earlier studies in which it was shown that increasing the dose of green tea or (-)-epigallocatechin gallate resulted in increased plasma C max values (41, 43, (59) (60) (61) . The data presented in Table 4 show that with increasing Polyphenon E intake, total flavan-3-ol metabolite excretion in urine increases in absolute amounts but remains relatively unchanged at ;10% when expressed as a percentage of intake. However, the (epi)gallocatechin metabolites, which (2) 0.9 6 0.2 0.6 6 0.1 1.1 6 0.3 Methyl-(epi)gallocatechin sulfates (6, 7) 3.9 6 1.4 2.0 6 0.5 3.6 6 0.6 Total (epi)gallocatechin metabolites 5.7 6 1.9 (26 6 9) 3.0 6 0.8 (5.5 6 1. were the minor components, behaved differently from the (-)-epicatechin metabolites. With the increasing dose, the (epi)catechin metabolites were excreted in greater quantities, but when expressed as a percentage of (-)-epicatechin and (1)-catechin intake, figures of 47 6 12%, 56 6 14%, and 45 6 4% were obtained, which are not significantly different. At the same time, (epi)gallocatechin metabolites are not excreted in higher quantities with the increasing dose with the excretion of 5.7 6 1.9 mmol, 3.0 6 0.8 mmol and 5.3 6 1.2 mmol for ingestion of 200 mg, 500 mg, and 1500 mg, respectively (Table  4) . This difference between (epi)catechin and (epi)gallocatechin could be explained by metabolic competition for phase II enzymes with reduced formation of (epi)gallocatechin conjugates at higher dose coupled with a transporter competition leading to a reduced efflux of (epi)gallocatechin from the intestinal lumen (62) . Such competition between (epi)catechin and (epi)gallocatechin could lead, at high doses of Polyphenon E, to the preferential absorption, metabolism, and subsequent excretion of (epi)catechin to the detriment of (epi)gallocatechin. Finally, it should be noted that although there were personto-person variations in the flavan-3-ol content of ileal fluid and the quantities of urinary metabolites that typify such feeding studies, this was not related to either the gender of the subjects or to whether or not they drank tea on a regular basis.
Other articles in this supplement include references (63) (64) (65) (66) (67) (68) (69) (70) (71) (72) .
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